View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Deals
March 31, 2022

Digitisation: deals drop significantly in clinical trial operations in H2 2021

This marks a deceleration in growth from the 54.5% decrease in deals that occurred in H1 2021 relative to the same period a year earlier.

By Data Journalism Team

In the second half of 2021 the number of deals relating to digitalisation decreased significantly by 78.6% from the same period in 2020.

This marks a deceleration in growth from the 54.5% decrease in deals that occurred in H1 2021 relative to the same period a year earlier.

GlobalData’s deals database looks at mergers, acquisitions and venture capital and private equity investments taking place daily between thousands of companies across the world.

During second half of 2021, deals relating to digitalisation accounted for 0.5% of all deals taking place in the sector. This represents a decrease from the figure of 0.9% in second half of 2020.

GlobalData's thematic approach to sector activity seeks to group key company information on investments to see which industries are best placed to deal with any issues they may encounter.

These themes, of which digitalisation is one, are best thought of as "any issue that keeps a CEO awake at night", and by tracking them, it becomes possible to ascertain which companies are leading the way on specific issues and which ones have some work to do.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU